Interventional Arm for Malignancies

Phase-Based Progress Estimates
University of Kentucky, Lexington, KY
Quality Improvement Practice Facilitation Intervention - Behavioral
All Sexes
What conditions do you have?

Study Summary

The overall goal of this study is to develop and pilot test the use of practice facilitation as an intervention for healthcare providers and staff, with the goal of improving the implementation of cancer prevention and screening guidelines in primary care settings.

Treatment Effectiveness

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 6 months

6 months
Colorectal Cancer: Screening Rate (Patient Population)
Lung Cancer: Screening Rate (Patient Population)
Tobacco: Treatment Rate (Patient Population)

Trial Safety

Trial Design

1 Treatment Group

Interventional Arm
1 of 1
Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: Interventional Arm · No Placebo Group · N/A

Interventional Arm
Experimental Group · 1 Intervention: Quality Improvement Practice Facilitation Intervention · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Trial Background

Prof. Pamela Hull, Associate Professor
Principal Investigator
University of Kentucky
Closest Location: University of Kentucky · Lexington, KY
Photo of Lexington  1Photo of Lexington  2Photo of Lexington  3
1999First Recorded Clinical Trial
4 TrialsResearching Malignancies
360 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.